EYPT (EyePoint) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EYPT EyePoint Inc EYPT
35 GF Score
Price $13.28
GF Value $0.76
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is EyePoint Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

EYPT
35GF Score
EyePoint Inc EYPT
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is EyePoint (EYPT) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of $13.28 is trading 1647.4% above its estimated GF Value™ of $0.76. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for EYPT:

  • Interest Received:
  • GF Value™: $0.76 vs. price of $13.28 (1647.4% above fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the EYPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EyePoint Business Description

Other Exchanges PV3B:Germany
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
35GF Score

Get the complete analysis for EYPT

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.28
Price
$0.76
GF Value